Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 1/2011

01.02.2011

Bone Disorders in Chronic Liver Diseases

verfasst von: Bruce A. Luxon

Erschienen in: Current Gastroenterology Reports | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Bone disease is a major complication of chronic liver disease. Osteomalacia is quite uncommon despite low vitamin D levels in the majority of patients with cirrhosis. In contrast, osteoporosis is quite common, occurring in up to 50% of patients. Osteoporosis can result in spontaneous or low-impact fractures in patients with chronic liver diseases, adversely affecting morbidity, quality of life, and survival. The general biology of osteoporosis, including its pathogenesis, diagnostic tools, and rationale for treatment, have been determined largely empirically from studies of postmenopausal women with osteoporosis. Treatment regimens with modification of risk factors, use of vitamin D, and supplementation with calcium and bisphosphonates have been shown to be effective in select groups of patients with chronic liver diseases.
Literatur
1.
Courbebaisse M, Souberbielle JC, Thervet E: Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 2010, 89(2):131–137.CrossRefPubMed
2.
Crawford BA, Labio ED, Strasser SI, et al.: Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol 2006, 3(12):689–699.CrossRefPubMed
3.
WHO: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994, 843:1–129.
4.
Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002, 50 Suppl 1(1):i1–9.
5.
Leslie WD, Bernstein CN, Leboff MS: AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003, 125(3):941–966.CrossRefPubMed
6.
Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312(7041):1254–1259.PubMed
7.
Stellon AJ, Webb A, Compston J, et al.: Low bone turnover state in primary biliary cirrhosis. Hepatology 1987, 7(1):137–142.CrossRefPubMed
8.
Guanabens N, Pares A: Liver and bone. Arch Biochem Biophys 2010, ePub ahead of print.
9.
Janes CH, Dickson ER, Okazaki R, et al.: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95(6):2581–2586.CrossRefPubMed
10.
Diamond TH, Stiel D, Lunzer M, et al.: Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989, 96(1):213–221.PubMed
11.
Cemborain A, Castilla-Cortazar I, Garcia M, et al.: Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 2000, 56(2):91–99.CrossRefPubMed
12.
Nakchbandi IA, van der Merwe SW: Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009, 6(11):660–670.CrossRefPubMed
13.
Ninkovic M, Love SA, Tom B, et al.: High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001, 69(6):321–326.CrossRefPubMed
14.
15.
Angulo P, Therneau TM, Jorgensen A, et al.: Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998, 29(5):729–735.CrossRefPubMed
16.
Guichelaar MM, Schmoll J, Malinchoc M, et al.: Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology 2007, 46(4):1198–1207.CrossRefPubMed
17.
Guanabens N, Pares A, Ros I, et al.: Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005, 42(4):573–577.CrossRefPubMed
18.
Solaymani-Dodaran M, Card TR, Aithal GP, et al.: Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006, 131(6):1752–1757.CrossRefPubMed
19.
Masaki K, Shiomi S, Kuroki T, et al.: Longitudinal changes of bone mineral content with age in patients with cirrhosis of the liver. J Gastroenterol 1998, 33(2):236–240.CrossRefPubMed
20.
Schiefke I, Fach A, Wiedmann M, et al.: Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005, 11(12):1843–1847.PubMed
21.
Guggenbuhl P, Deugnier Y, Boisdet JF, et al.: Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005, 16(12):1809–1814.CrossRefPubMed
22.
Peris P, Guanabens N, Pares A, et al.: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57(2):111–114.CrossRefPubMed
23.
Navasa M, Monegal A, Guanabens N, et al.: Bone fractures in liver transplant patients. Br J Rheumatol 1994, 33(1):52–55.CrossRefPubMed
24.
Sokhi RP, Anantharaju A, Kondaveeti R, et al.: Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004, 10(5):648–653.CrossRefPubMed
25.
Eastell R, Dickson ER, Hodgson SF, et al.: Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991, 14(2):296–300.CrossRefPubMed
26.
Atamaz F, Hepguler S, Karasu Z, et al.: The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 2006, 38(5):1448–1452.CrossRefPubMed
27.
Pares A, Guanabens N, Pares A, et al.: Treatment of bone disorders in liver disease. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. J Hepatol 2006, 45(3):445–453.
28.
• Pares A, Guanabens N: Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008, 12(2):407–424. A good review of osteoporosis in primary biliary cirrhosis with discussions about the prevalence, pathogenesis, and recommendations for treatment. CrossRefPubMed
29.
Crippin JS, Jorgensen RA, Dickson ER, et al.: Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994, 89(1):47–50.PubMed
30.
Shiomi S, Masaki K, Habu D, et al.: Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol 1999, 34(2):241–245.CrossRefPubMed
31.
Guanabens N, Pares A, Ros I, et al.: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003, 98(10):2268–2274.PubMed
32.
•• Zein CO, Jorgensen RA, Clarke B, et al.: Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005, 42(4):762–771. This is the only randomized, placebo-controlled trial of a bisphosphonate in patients with primary biliary cirrhosis. CrossRefPubMed
33.
Guanabens N, Enjuanes A, Alvarez L, et al.: High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J Bone Miner Metab 2009, 27(3):347–354.CrossRefPubMed
34.
Monegal A, Guanabens N, Suarez MJ, et al.: Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009, 22(2):198–206.CrossRefPubMed
35.
Crawford BA, Kam C, Pavlovic J, et al.: Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144(4):239–248.PubMed
36.
Olsson R, Mattsson LA, Obrant K, et al.: Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999, 19(3):188–192.CrossRefPubMed
37.
Hulley S, Furberg C, Barrett-Connor E, et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jama 2002, 288(1):58–66.CrossRefPubMed
38.
Levy C, Harnois DM, Angulo P, et al.: Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005, 25(1):117–121.CrossRefPubMed
39.
Floreani A, Zappala F, Fries W, et al.: A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997, 24(4):239–244.CrossRefPubMed
40.
Camisasca M, Crosignani A, Battezzati PM, et al.: Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994, 20(3):633–637.CrossRefPubMed
41.
Feitelberg S, Epstein S, Ismail F, et al.: Deranged bone mineral metabolism in chronic alcoholism. Metabolism 1987, 36(4):322–326.CrossRefPubMed
42.
Laitinen K, Karkkainen M, Lalla M, et al.: Is alcohol an osteoporosis-inducing agent for young and middle-aged women? Metabolism 1993, 42(7):875–881.CrossRefPubMed
43.
Mitchison HC, Malcolm AJ, Bassendine MF, et al.: Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988, 94(2):463–470.PubMed
44.
Van Berkum FN, Beukers R, Birkenhager JC, et al.: Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. Gastroenterology 1990, 99(4):1134–1139.PubMed
45.
Guanabens N, Pares A, Marinoso L, et al.: Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990, 85(10):1356–1362.PubMed
46.
Lindor KD, Janes CH, Crippin JS, et al.: Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995, 21(2):389–392.PubMed
47.
• Guichelaar MM, Kendall R, Malinchoc M, et al.: Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006, 12(9):1390–1402. A thorough review of hepatic osteodystrophy in patients with end stage liver disease before and after liver transplantation. Recommendations are given for screening patients for osteoporosis and for treatment. CrossRefPubMed
48.
Chen CC, Wang SS, Jeng FS, et al.: Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996, 11(5):417–421.CrossRefPubMed
49.
Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al.: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28(3):695–699.CrossRefPubMed
50.
Bonkovsky HL, Hawkins M, Steinberg K, et al.: Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990, 12(2):273–280.CrossRefPubMed
51.
Monegal A, Navasa M, Guanabens N, et al.: Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997, 60(2):148–154.CrossRefPubMed
52.
Sinigaglia L, Fargion S, Fracanzani AL, et al.: Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997, 24(9):1809–1813.PubMed
53.
Pares A, Guanabens N, and Ros I: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Hepatology 1999, 30:472A.CrossRef
54.
Epstein O, Kato Y, Dick R, et al.: Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982, 36(3):426–430.PubMed
55.
Guanabens N, Pares A, Monegal A, et al.: Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997, 113(1):219–224.CrossRefPubMed
56.
Wolfhagen FH, van Buuren HR, den Ouden JW, et al.: Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997, 26(2):325–330.CrossRefPubMed
Metadaten
Titel
Bone Disorders in Chronic Liver Diseases
verfasst von
Bruce A. Luxon
Publikationsdatum
01.02.2011
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 1/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0166-4

Weitere Artikel der Ausgabe 1/2011

Current Gastroenterology Reports 1/2011 Zur Ausgabe

ReviewPaper

Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy

ReviewPaper

Management of Refractory Ascites and Hepatorenal Syndrome

CLINICAL TRIAL REPORT

Clinical Trial Report: Treatment of Nonalcoholic Steatohepatitis with Vitamin E

ReviewPaper

Big Changes Are Coming in Hepatitis C

ReviewPaper

The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection

ReviewPaper

Management of Portal Hypertension in Children

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise